General Biologicals Corporation
4117
Rank in Stocks
#27058
General Biologicals Corporation (GBC) is a company dedicated to the research,... General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally, GBC provides essential blood screening services for detecting hepatitis and HIV, alongside crucial biomaterials such as antibody preparations and human plasma. Venturing beyond diagnostics, the company also markets a line of oral care products under its proprietary 'oh care' brand. These diagnostic systems are primarily utilized by clinics and laboratories. Founded in 1973, General Biologicals Corporation is headquartered in Hsinchu City, Taiwan.
Share Price
$0.24082722
Last synced: 2026-11-10
Market Cap
$16.94M
Change (1 day)
-3.07%
Change (1 year)
-39.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade General Biologicals Corporation (4117)
Category
Healthcare
Operating Margin for General Biologicals Corporation (4117)
Operating Margin as of November 2026 TTM: -65.68%
According to General Biologicals Corporation's latest financial reports, its current operating margin (TTM) is -65.68%. At the end of 2025 the company had an operating margin of -101.22%.
Operating Margin history for General Biologicals Corporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -65.68% | -35.11% |
| 2025 | -101.22% | 19.63% |
| 2024 | -84.61% | 31.85% |
| 2023 | -64.17% | 481.78% |
| 2022 | -11.03% | -238.92% |
| 2021 | 7.94% | -12.84% |
| 2020 | 9.11% | -163.22% |
| 2019 | -14.41% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 18.91% | -100.29% |
IE
|
|
| 10.95% | -100.17% |
CN
|
|
| 25.26% | -100.38% |
CH
|
|
| 13.54% | -100.21% |
CH
|
|
| 38.62% | -100.59% |
CN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about General Biologicals Corporation's operating margin
What is General Biologicals Corporation's operating margin?
General Biologicals Corporation's operating margin is -65.68%, as of Nov 2026.
What was General Biologicals Corporation's operating margin in 2025?
In 2025, General Biologicals Corporation's operating margin was -101.22%, compared with -84.61% in 2024.
How has General Biologicals Corporation's operating margin changed since 2020?
From 2020 to 2025, General Biologicals Corporation's operating margin was highest in 2020 (9.11%) and lowest in 2025 (-101.22%).
How does General Biologicals Corporation's operating margin compare with similar companies?
General Biologicals Corporation's operating margin (-65.68%) is lower than that of all 5 similar companies listed above. The highest among them is Jafron Biomedical Co.,Ltd., with 38.62%.